Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 2/2014

01-09-2014 | Laboratory Investigation

A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma

Authors: Ye Song, Zheng Hu, Hao Long, Yuping Peng, Xi’an Zhang, Tianshi Que, Shihao Zheng, Zhiyong Li, Gang Wang, Liu Yi, Zhen Liu, Weiyi Fang, Songtao Qi

Published in: Journal of Neuro-Oncology | Issue 2/2014

Login to get access

Abstract

HDGF is overexpressed in gliomas as compared to normal brain. We therefore analyzed the molecular mechanisms of HDGF action in gliomas. HDGF was downregulated in normal brain tissue as compared to glioma specimens at both the mRNA and the protein levels. In glioma samples, increased HDGF expression was associated with disease progression. Knocking down HDGF expression not only significantly decreased cellular proliferation, migration, invasion, and tumorigenesis, but also markedly enhanced TMZ-induced cytotoxicity and apoptosis in glioma cells. Mechanistic analyses revealed that CCND1, c-myc, and TGF-β were downregulated after stable HDGF knockdown in the U251 and U87 glioma cells. HDGF knockdown restored E-cadherin expression and suppressed mesenchymal cell markers such as vimentin, β-catenin, and N-cadherin. The expression of cleaved caspase-3 increased, while Bcl-2 decreased in each cell line following treatment with shHDGF and TMZ, as compared to TMZ alone. Furthermore, RNAi-based knockdown study revealed that HDGF is probably involved in the activation of both the PI3K/Akt and the TGF-β signaling pathways. Together, our data suggested that HDGF regulates glioma cell growth, apoptosis and epithelial–mesenchymal transition (EMT) probably through the Akt and the TGF-β signaling pathways. These results provide evidence that targeting HDGF or its downstream targets may lead to novel therapies for gliomas.
Appendix
Available only for authorised users
Literature
1.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRef
2.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
3.
Wang Y, Jiang T (2013) Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 331:139–146PubMedCrossRef
4.
5.
Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, Yamamoto H, Kishimoto T (1994) Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 269:25143–25149PubMed
6.
Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA (2000) Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 105:567–575PubMedCentralPubMedCrossRef
7.
Enomoto H, Yoshida K, Kishima Y, Okuda Y, Nakamura H (2002) Participation of hepatoma-derived growth factor in the regulation of fetal hepatocyte proliferation. J Gastroenterol 37(Suppl 14):158–161PubMedCrossRef
8.
9.
Kishima Y, Yamamoto H, Izumoto Y, Yoshida K, Enomoto H, Yamamoto M, Kuroda T, Ito H, Yoshizaki K, Nakamura H (2002) Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 277:10315–10322PubMedCrossRef
10.
Matsuyama A, Inoue H, Shibuta K, Tanaka Y, Barnard GF, Sugimachi K, Mori M (2001) Hepatoma-derived growth factor is associated with reduced sensitivity to irradiation in esophageal cancer. Cancer Res 61:5714–5717PubMed
11.
Kishima Y, Yoshida K, Enomoto H, Yamamoto M, Kuroda T, Okuda Y, Uyama H, Nakamura H (2002) Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells. Hepatogastroenterology 49:1639–1644PubMed
12.
Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, Doki Y, Yoshida K, Aozasa K, Nakamura H, Monden M (2006) Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12:117–122PubMedCrossRef
13.
Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L (2006) Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66:18–23PubMedCrossRef
14.
Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M, Aozasa K, Kawase I, Hayashi N, Monden M (2006) Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12:6043–6048PubMedCrossRef
15.
Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, Hung CH, Chen CH, Lu SN, Lee CM, Changchien CS, Hu TH (2007) Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer 121:1059–1065PubMedCrossRef
16.
Zhou Y, Zhou N, Fang W, Huo J (2010) Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol 5:58PubMedCentralPubMedCrossRef
17.
Wang S, Fang W (2011) Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma. Histopathology 58:217–224PubMedCrossRef
18.
Hsu SS, Chen CH, Liu GS, Tai MH, Wang JS, Wu JC, Kung ML, Chan EC, Liu LF (2012) Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J Neurooncol 107:101–109PubMedCrossRef
19.
Zhang A, Long W, Guo Z, Guo Z, Cao BB (2012) Downregulation of hepatoma-derived growth factor suppresses the malignant phenotype of U87 human glioma cells. Oncol Rep 28:62–68PubMed
20.
Qi S, Song Y, Peng Y, Wang H, Long H, Yu X, Li Z, Fang L, Wu A, Luo W, Zhen Y, Zhou Y, Chen Y, Mai C, Liu Z, Fang W (2012) ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One 7:e38842PubMedCentralPubMedCrossRef
21.
Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, Yao K, Wu B, Fang W (2010) Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 10:270PubMedCentralPubMedCrossRef
22.
Zhen Y, Ye Y, Yu X, Mai C, Zhou Y, Chen Y, Yang H, Lyu X, Song Y, Wu Q, Fu Q, Zhao M, Hua S, Wang H, Liu Z, Zhang Y, Fang W (2013) Reduced CTGF expression promotes cell growth, migration, and invasion in nasopharyngeal carcinoma. PLoS One 8:e64976PubMedCentralPubMedCrossRef
23.
Crossin KL, Tai MH, Krushel LA, Mauro VP, Edelman GM (1997) Glucocorticoid receptor pathways are involved in the inhibition of astrocyte proliferation. Proc Natl Acad Sci USA 94:2687–2692PubMedCentralPubMedCrossRef
24.
Zhao J, Yu H, Lin L, Tu J, Cai L, Chen Y, Zhong F, Lin C, He F, Yang P (2011) Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF). J Proteomics 75:588–602PubMedCrossRef
25.
Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, Chang HW, Changchien CS, Lee CM, Chuang JH, Tai MH (2003) Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 98:1444–1456PubMedCrossRef
26.
Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, Sakon M, Kawase I, Monden M, Nakamura H (2006) Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 13:159–167PubMedCrossRef
27.
Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, Kuo HM, Tsai HE, Lin YW, Wen ZH, Liu JK, Yeh MH, Tai MH (2012) Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial–mesenchymal transition. J Pathol 228:158–169PubMedCrossRef
28.
Yamamoto T, Nakamura H, Liu W, Cao K, Yoshikawa S, Enomoto H, Iwata Y, Koh N, Saito M, Imanishi H, Shimomura S, Iijima H, Hada T, Nishiguchi S (2009) Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2). J Gastroenterol 44:228–235PubMedCrossRef
29.
Chen X, Yun J, Fei F, Yi J, Tian R, Li S, Gan X (2012) Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer. Pathol Res Pract 208:437–443PubMedCrossRef
30.
Stevens B, Fields RD (2002) Regulation of the cell cycle in normal and pathological glia. Neuroscientist 8:93–97PubMedCrossRef
31.
32.
33.
Li GQ, Zhang Y, Liu D, Qian YY, Zhang H, Guo SY, Sunagawa M, Hisamitsu T, Liu YQ (2013) PI3 kinase/Akt/HIF-1alpha pathway is associated with hypoxia-induced epithelial-mesenchymal transition in fibroblast-like synoviocytes of rheumatoid arthritis. Mol Cell Biochem 372:221–231PubMedCrossRef
34.
Han L, Yang Y, Yue X, Huang K, Liu X, Pu P, Jiang H, Yan W, Jiang T, Kang C (2010) Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of beta-catenin-mediated transcription. Brain Res 1366:9–17PubMedCrossRef
35.
Miyazono K, Ehata S, Koinuma D (2012) Tumor-promoting functions of transforming growth factor-beta in progression of cancer. Ups J Med Sci 117:143–152PubMedCentralPubMedCrossRef
36.
Kaminska B, Kocyk M, Kijewska M (2013) TGF beta signaling and its role in glioma pathogenesis. Adv Exp Med Biol 986:171–187PubMedCrossRef
37.
Jennings MT, Pietenpol JA (1998) The role of transforming growth factor beta in glioma progression. J Neurooncol 36:123–140PubMedCrossRef
38.
Wick W, Platten M, Weller M (2001) Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53:177–185PubMedCrossRef
39.
Carlson ME, Hsu M, Conboy IM (2008) Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 454:528–532PubMedCrossRef
40.
Fischer AN, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W (2007) PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 26:3395–3405PubMedCrossRef
41.
Kahlert UD, Nikkhah G, Maciaczyk J (2013) Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett 331:131–138PubMedCrossRef
42.
Wen W, Ding J, Sun W, Fu J, Chen Y, Wu K, Ning B, Han T, Huang L, Chen C, Xie D, Li Z, Feng G, Wu M, Xie W, Wang H (2012) Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression. Hepatology 55:1787–1798PubMedCrossRef
43.
Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK, Kim HK, Kim JS, Oh SC (2011) Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res 71:7061–7070PubMedCrossRef
44.
Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890PubMedCrossRef
45.
Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19:156–172PubMedCrossRef
46.
Heldin CH, Vanlandewijck M, Moustakas A (2012) Regulation of EMT by TGF-beta in cancer. FEBS Lett 586:1959–1970PubMedCrossRef
47.
Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199PubMedCrossRef
Metadata
Title
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma
Authors
Ye Song
Zheng Hu
Hao Long
Yuping Peng
Xi’an Zhang
Tianshi Que
Shihao Zheng
Zhiyong Li
Gang Wang
Liu Yi
Zhen Liu
Weiyi Fang
Songtao Qi
Publication date
01-09-2014
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1512-4

Other articles of this Issue 2/2014

Journal of Neuro-Oncology 2/2014 Go to the issue

Clinical Study

Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study

Clinical Study

Prophylactic plastic surgery closure of neurosurgical scalp incisions reduces the incidence of wound complications in previously-operated patients treated with bevacizumab (Avastin®) and radiation

Letter to the Editor

Unusual coincidence of a pituitary adenoma and an aspergilloma of the sphenoid sinus

Clinical Study

Clinical presentation and patterns of care for short-term survivors of malignant glioma

Clinical Study

Combined salvage therapies for recurrent glioblastoma multiforme: evaluation of an interdisciplinary treatment algorithm

Clinical Study

Structural brain alterations in children an average of 5 years after surgery and chemotherapy for brain tumors